Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10509584 | 0.98 | HRH3 (0.48) | MEN1KMT2AHRH3KDM4EHTR1A | |
| SCHEMBL12371260 | 0.98 | MEN1 (0.50) | MEN1KMT2AHRH3KDM4EHTR1A | |
| SCHEMBL10679639 | 0.98 | MEN1 (0.50) | MEN1KMT2AHRH3KDM4EHTR1A | |
| SCHEMBL17528474 | 0.98 | MEN1 (0.50) | MEN1KMT2AHRH3KDM4EHTR1A | |
| SCHEMBL4650639 | 0.98 | HRH3 (0.48) | MEN1KMT2AHRH3KDM4EHTR1A | |
| SCHEMBL1469605 | 0.96 | TSHR (0.48) | MEN1KMT2AHRH3KDM4EHTR1A | |
| SCHEMBL22266158 | 0.92 | HRH3 (0.48) | HRH3KDM4EHTR1AMAPK1SMN1; SMN2 | |
| SCHEMBL18024038 | 0.89 | HRH3 (0.53) | HRH3MAPK1SMN1; SMN2CYP1A2 | |
| SCHEMBL31305372 | 0.89 | MEN1 (0.55) | MEN1KMT2AKDM4EHTR1AMAPK1 | |
| SCHEMBL31305373 | 0.89 | MEN1 (0.55) | MEN1KMT2AKDM4EHTR1AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3111940-B1 | SILICON PHTHALOCYANINE COMPLEX, PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF | SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO LTD (CN) | 2018-03-21 | — | — | EP | disclosed |
| US-9890181-B2 | Silicon phthalocyanine complex, preparation method and medicinal application thereof | SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-02-13 | — | — | US | disclosed |
| US-9890181-B2 | Silicon phthalocyanine complex, preparation method and medicinal application thereof | SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-02-13 | — | — | US | disclosed |
| EP-2598507-B1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2017-05-31 | — | — | EP | disclosed |
| US-20170002028-A1 | SILICON PHTHALOCYANINE COMPLEX, PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF | SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD. (CN) | 2017-01-05 | — | — | US | disclosed |
| US-20170002028-A1 | SILICON PHTHALOCYANINE COMPLEX, PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF | SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD. (CN) | 2017-01-05 | — | — | US | disclosed |
| EP-3111940-A1 | SILICON PHTHALOCYANINE COMPLEX, PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF | Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CN) | 2017-01-04 | — | — | EP | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-9056914-B2 | Anticancer derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2015-06-16 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| WO-2012014147-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002028-A1 | SILICON PHTHALOCYANINE COMPLEX, PREPARATION METHOD AND MEDICINAL APPLICATION THEREOF | SRI, SCLY, PPIC | MEN1 16/4885KMT2A 2055/4885HRH3 3573/4885 |
| US-20130137659-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MCL1, TP53, MYC | MEN1 1049/4885KMT2A 3275/4885HRH3 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.